ExeVir Bio
Budget
€10 — €0
EP Access
0
accredited persons
Staff
1
0.1 FTE
EU Grants
None
Mission & Goals
ExeVir is a clinical-stage company developing novel antibody therapies that help patients ward off infectious diseases. Our focus is to protect populations unable to benefit from vaccines, such as immunocompromised individuals. The versatile VHH platform enables both prevention and treatment of bacterial and viral threats.
EU Legislative Interests
- EU Strategy on COVID-19 and infectious diseases Therapeutics - A Pharmaceutical Strategy for Europe - Horizon Europe
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Flanders Bio Biovia
Organisation Members
https://flanders.bio/en/member-directory/exevir-bio https://biovia.be/
Commissioner Meetings
No recorded meetings with EU commissioners.